Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $734.65, giving the company a market capitalization of 77.47B. It carries a P/E multiple of 16.82 and pays a dividend yield of 37.6%.
On 2025-11-21, Regeneron(REGN) stock moved within a range of $720.02 to $753.51. With shares now at $734.65, the stock is trading +2.0% above its intraday low and -2.5% below the session's peak.
Trading activity shows a volume of 2.29M, compared to an average daily volume of 1.24M.
The stock's 52-week range extends from a low of $476.49 to a high of $800.99.
The stock's 52-week range extends from a low of $476.49 to a high of $800.99.
REGN News
In November 2025, Regeneron Pharmaceuticals announced a series of major product milestones, including FDA approvals for EYLEA HD® in expanded indications and do...
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) Eylea HD (aflibercept) Injection 8 mg for pati...
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron and keeping the price target at $725.00. TipRanks Black Friday Sale Claim 60% off T...
Analyst ratings
67%
of 30 ratingsMore REGN News
Regeneron, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst John Newman from Canaccord Genuity maintained a Buy rating o...
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Regeneron (REGN) to $700 from $615 and keeps an Equal Weight rating on the shares. The firm t...
Regeneron (REGN) announced that the FDA has approved Eylea HD Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion w...
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...
The Regeneron Pharmaceuticals, Inc. ( ) share price has done very well over the last month, posting an excellent gain of 25%. The bad news is that even after th...
Regeneron Pharmaceuticals (REGN) has received approval from the European Commission for Libtayo (cemiplimab), to be used as an adjuvant treatment for adults wit...
Regeneron (REGN) Pharmaceuticals announced that the European Commission, EC, has approved the PD-1 inhibitor Libtayo as an adjuvant treatment for adult patients...